Reversal of increases in methadone distribution for opioid use disorder in the US during the COVID-19 pandemic

Amy L. Kennalley MS[a], Jessica L. Fanelli BS[a], John A. Furst Jr. BS[a], Nicholas J. Mynarski BS[a], Stephanie D. Nichols PharmD, MPH[b], Kenneth L. McCall PharmD[c], Brian J. Piper PhD[a,d]

[a]Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, 18510

[b]Department of Pharmacy Practice, University of New England, Portland, ME 04103

[c]Department of Pharmacy Practice, Binghamton University, Johnson City, NY 13790

[d]Center for Pharmacy Innovation and Outcomes, Forty Fort, PA, 18704

Corresponding Author: Amy L. Kennalley, MS

525 Pine St, Scranton, PA 18510

(925) 408-5226; amykennalley@gmail.com; akennalley@som.geisinger.edu

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declarations of interest: BJP is supported by the Health Resources Services Administration (D34HP31025), the Pennsylvania Academic Clinical Research Center, and was (until 12/31/2021) part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no disclosures.

Abstract: 341 words

Highlights

- Methadone is distributed to opioid treatment programs (OTP) for opioid use disorder
- Amount of methadone distributed to OTPs significantly increased from 2010 to 2021
- Methadone distribution was 5.69% lower in 2021 than 2019, and 5.71% lower than 2020
- Almost all (99.99%) of methadone covered by Medicaid was prescribed in twelve states
- There were large state level disparities in methadone distribution to OTPs

Abstract

Introduction: This study aimed to investigate US patterns of distribution of methadone for OUD from 2010 to 2021 in order to identify potential obstacles in the mitigation of the opioid epidemic. **Methods:** The number of Opioid Treatment Programs (OTP) per state, and the weight of methadone in grams distributed to OTPs per state, were obtained from the US Drug Enforcement Administration's Automated Reports and Consolidated Ordering System. Methadone was adjusted for state population and compared across all fifty states and Washington DC from 2010 to 2021. Medicaid's State Drug Utilization Data database was utilized to determine methadone prescriptions for all fifty states and DC. This was corrected for the number of Medicaid enrollees in each state. **Results:** The overall distribution of methadone to OTPs significantly increased from 2010 to 2020 (+61.00%) and from 2015 to 2020 (+26.22%) (P < 0.0001). The states with the highest percent change from 2010 to 2020 were Montana (+897.02%), Alaska (+421.11%), and Vermont (+353.67%). In contrast to 2010 and 2015, 2019 (pre-COVID-19 pandemic) to 2021 (post-pandemic) showed no significant change in the US distribution of methadone to OTPs (-5.15%). From 2019 to 2021, methadone distribution in Ohio (+47.53%) significantly increased while it significantly decreased in Florida (-54.61%), New Hampshire (-52.99%), Nebraska (-47.96%), and Alabama (-44.27%) relative to the national mean. Twenty states (MD, VT, NM, ME, GA, NC, NY, NH, UT, OK, SC, MT, WA, AL, TX, MN, FL, SD, NE and MS) had fewer OTPs in 2021 relative to prior years. In 2020, 89.23% of methadone covered by Medicaid was distributed among three states (VA, MT, IA), and seven states (VA, MT, IA, WI, TN, OR, VT) distributed 98.47%. **Conclusions:** This investigation revealed three patterns for methadone distribution in

the US: 1) increased utilization over the past decade, 2) a decline from 2019 to 2021,

and 3) pronounced state level variation with some states (e.g. Wyoming) having no

OTPs or Medicaid coverage. New policies are urgently needed to remove access

barriers to methadone treatment in order to reduce the worsening overdose crisis in the

US.

Keywords: Opioid Treatment Programs, COVID-19, Opiate, Addiction, Medicaid,

Addiction Treatment

Introduction

The United States (US) Food and Drug Administration (FDA) has approved methadone, buprenorphine, and naltrexone as treatments for Opioid Use Disorder (OUD) (Peterkin et al., 2022). Methadone is a long-acting synthetic opioid used to treat OUD via opioid treatment programs (OTP) (Anderson & Kearney, 2000; Peterkin et al., 2022; Toce et al., 2018). There have been several policy changes impacting OUD care during the COVID-19 pandemic. Methadone take-home doses have been extended to 28 days for stable patients and 14 days for less stable patients, drug screening requirements have been relaxed, and telemedicine has been expanded for established patients (Kennalley et al., 2021; Substance Abuse and Mental Health Services Administration, 2020). However, unlike for buprenorphine, starting methadone treatment required an in-person visit. Prior to the pandemic, OUD methadone treatment also required the co-administration of counseling, however, these counseling requirements have also been relaxed as a result of the COVID-19 pandemic (Mattick et al., 2009; Substance Abuse and Mental Health Services Administration, 2020).

Methadone treatment, though considered a gold standard treatment for OUD, is not without serious adverse effects similar to other opioids: respiratory depression and cardiotoxicity (Jones et al., 2022; Kaufman et al., 2022; Toce et al., 2018). An alternative standard treatment to methadone, buprenorphine, has also raised safety concerns as well with rising respiratory depression fatalities after oral doses in both adult and pediatric patients (Darracq & Thornton, 2021). It is important to contextualize these concerns with the extremely high risk of respiratory depression associated with ongoing nonprescribed IV opioid use, a symptom of under or untreated OUD. In addition

to its adverse effects, buprenorphine was widely but inequitably unavailable from 2004 to 2015 due to factors such as race and socioeconomic status, finding that the Black population had a statistically lower probability of receiving a prescription (Lagisetty et al., 2019). To further bolster the use for methadone for OUD, treatment with methadone was superior to buprenorphine in reducing criminal activity, HIV infection, hepatitis, and overall mortality (Anderson & Kearney, 2000; Calcaterra et al., 2019; Jones et al., 2019; Marsch, 1998; Otiashvili et al., 2013). Additionally, a Cochrane Review concluded that methadone was superior to buprenorphine in retaining patients in treatment (Supplemental Table 1) (Mattick et al., 2014).

There have been over one-million drug overdoses in the US since the start of the opioid epidemic (Centers for Disease Control and Prevention, 2022). The COVID-19 pandemic has placed tremendous stress on the health care system including the access to providers and availability of OUD treatments. Between 2019 and 2020, there was a +48.8% increase in overdose mortality among Black people, compared to +26.3% among White people (Friedman & Hansen, 2022). Moreover, from April 2020 to April 2021, the number of drug overdoses in the US exceeded one-hundred thousand, a +28.5% increase over the previous year (Centers for Disease Control and Prevention, 2021). With a +60% rise in overdoses compared to the previous year, May 2020 became the deadliest month on record (Friedman & Akre, 2021). A cross-sectional study, conducted from May to June 2020 in the US and Canada, found that new patients wishing to initiate methadone treatment were faced with a barrier in 20% of clinics (Joudrey et al., 2021). Similarly, prior to the pandemic, both methadone and buprenorphine-based OTPs were found to be effective in US jails and prisons; however,

following the pandemic, some of these OTPs have been discontinued while others have

been expanded (Bandara et al., 2020; Bandara et al., 2021; Maine Department of

Corrections, 2020). Together, it is critical to examine the changes in methadone

distribution during the COVID-19 pandemic and determine whether there are national or

regional barriers to access this evidence-based pharmacotherapy.

Material and Methods

Procedures

The quantities of methadone distributed (in grams) were obtained from the Drug Enforcement Administration's (DEA) Automated Reports and Consolidated Ordering System (ARCOS) yearly drug summary reports for 2010, 2015, 2019, 2020 and 2021. ARCOS is a federal program mandated by the 1970 Controlled Substances Act to track the distribution of DEA controlled substances from retail pharmacies, hospitals, practitioners, teaching institutions, mid-level practitioners, and OTPs. Previous pharmacoepidemiologic studies have utilized the ARCOS database (Furst et al., 2022; Kennalley et al., 2022; Piper et al., 2021). Methadone distributed to OTPs was classified as an OUD treatment. The number of OTPs per state were also obtained from ARCOS yearly drug summary reports for the years 2010, 2015, 2019, 2020 and 2021. The state population estimates, including the District of Colombia (DC), were derived from the US Census Bureau's Annual Estimates of the Resident Population for the US (United States Census Bureau, 2021). The US Territories were examined elsewhere and were not included in Figures 1-5 (Cabrera et al., 2019).

Medicaid is a program at the federal and state level which functions to aid in covering healthcare costs for patients with limited resources (Chorniy et al., 2018). Medicaid.gov publishes all prescription drugs covered by Medicaid every year for all 50 states and DC in the State Drug Utilization Data (SDUD) database (Medicaid.gov, 2021). Data was collected for methadone covered by Medicaid in 2020 for all 50 states and DC using a filtered download from the SDUD database. National Drug Codes of formulations that were used are provided in Supplemental Table 2. The number of

methadone prescriptions per state was divided by the number of Medicaid enrollees per state in 2020. This study was approved by the institutional review boards of the University of New England and Geisinger.

Data Analysis

The percent change in methadone distribution for OUD was compared between states for time spans of ten years, five years and one year respectively. The distribution of methadone, corrected for population, was compared between 2010 and 2020, 2010 and 2021, 2015 and 2020, 2015 and 2021, 2019 and 2020, 2019 and 2021, and 2020 and 2021 were considered significant if the paired t-test indicated $P < 0.05$. Any state with percent changes greater than ±1.96 SDs from the national average percent change was considered statistically significant. The number of OTPs per one million persons per state between years—2010 and 2015, 2010 and 2020, 2010 and 2021, 2015 and 2020, 2015 and 2021, 2020 and 2021—were considered significant if the t-test indicated $P < 0.05$. Heatmaps created using JMP version 16.2.0. Figures and data analysis completed using Microsoft Excel and GraphPad Prism version 9.4.0.

Results

Overall, the total volume of methadone distributed to OTPs in the US increased over the last decade. The amount distributed to OTPs was 8.62 metric tons in 2010, 10.88 tons in 2015 (+26.3%), and 13.03 tons in 2020 (+19.7%), reflecting an increase in distribution to the majority of states. Specifically, the national distribution of methadone for OUD from 2010 to 2020 increased by +96.96% (SD=146.64) on average, with forty-three states showing an increase, five states a decrease, and three states showing no change. A t-test revealed a significant increase (+61.8%) from 2010 to 2019 (P < 0.0001) and by +61.0% from 2010 to 2020 (P < 0.0001). From 2010 to 2020, there was a large (> 1.5 SDs) increase in Vermont (+353.67%), and significant elevations (> 1.96 SDs, P < 0.05) in Alaska (+421.11%) and Montana (+897.02%) relative to the average (Figure 1).

Examination of 2015 relative to 2020 revealed the national average distribution for OUD increased by +26.22% (SD = 50.38%), with thirty-eight states increasing but eleven states decreasing. A t-test again revealed a significant (P < 0.0001) increase. There were significant increases (P < 0.05) in Alaska (+135.34%) and Mississippi (+311.48%) relative to the national mean (Figure 2).

However, from 2019 to 2020 (i.e., pre- to post- COVID-19 pandemic), the distribution of methadone was stable (-0.091%, SD = 10.81%). Slightly over half (twenty-eight) of states showed an increase and twenty-two states exhibited a decrease. No significant (P = 0.76) differences were found between 2019 and 2020. Examination of specific states revealed an increase in Kentucky (+18.68%) and a significant increase (P < 0.05) in Ohio (+26.02%) relative to the national mean. In

contrast, there were appreciable decreases in Nebraska (-16.6%), South Dakota (-17.27%), and Mississippi (-20.53%), and significant decreases ($P < 0.05$) in Alabama (-21.96%), New Hampshire (-24.13%) and Florida (-28.97%) relative to the national mean (Figure 3).

Looking at 2019 to 2021, a wider pre- to post COVID-19 pandemic timeline, the distribution of methadone from was also fairly stable (-5.15%, SD = 19.14%). Eighteen states showed an increase while thirty-one states showed a decrease. No significant ($P = 0.065$) differences were found between 2019 and 2021. Ohio (+47.53%) had a significant increase ($P < 0.05$) relative to the national mean. In contrast, there was an appreciable decrease in Mississippi (-42.53%), and significant decreases ($P < 0.05$) in Alabama (-44.27%), Nebraska (-47.96), New Hampshire (-52.99%) and Florida (-54.61%) relative to the national mean (Figure 4). However, distribution in 2021 was -5.69% lower than 2019 and -5.71% lower than 2020 (Supplemental Figure 1A).

The average methadone distribution in the US for OUD was 43.75 mg/person (SD = 35.01) in 2021. There was significantly elevated methadone distributed in Rhode Island (155.13 mg/person), Delaware (147.27 mg/person), Connecticut (126.66 mg/person), and Vermont (125.06 mg/person) relative to the national mean (43.75, $P < 0.05$).

The total number of OTPs distributing methadone increased +18.6% from 2010 (1,139) to 2015 (1,351) and peaked in 2021 (1,738, Supplemental Figure 1B). The number of pharmacies distributing buprenorphine (49,041) was 43.1-fold greater than OTPs distributing methadone in 2010. However, this ratio decreased to 33.3-fold in 2021. The number of OTPs per 1 million persons per state significantly increased ($P <$

0.0001) from 2010 to 2021. A t-test indicated that 2010 to 2015 (P < 0.0001), 2010 to 2020 (P < 0.0001), 2010 to 2021 (P < 0.0001), 2015 to 2020 (P < 0.0001), and 2015 to 2021 (P < 0.0001) were each significantly different. The number of OTPs per 1 million persons per state in 2020 relative to 2021 (P = 0.1741), and 2019 relative to 2021 (P = 0.0652) did not significantly increase. Twenty states had fewer OTPs in 2021 relative to 2010, 2015, or 2010 (Maryland, Vermont, New Mexico, Maine, Georgia, North Carolina, New York, New Hampshire, Utah, Oklahoma, South Carolina, Montana, Washington, Alabama, Texas, Minnesota, Florida, South Dakota, Nebraska, and Mississippi). One state (Wyoming) did not have a single OTP (Figure 5, Supplemental Table 3).

The SDUD database showed considerable variations in methadone distribution between states and regions for patients covered under Medicaid. Virginia, Iowa, and Montana constituted 89.23% of all methadone covered under Medicaid in the US in 2020. The top seven states (Virginia, Montana, Iowa, Wisconsin, Tennessee, Oregon, and Vermont) accounted for 98.47% of all methadone covered by Medicaid in 2020 (Figure 6).

Discussion

The key finding of this study was that the pronounced and significant increase in methadone distribution to OTPs for OUD over the past decade has reversed with a non-significant decrease (-0.09%) from 2019 to 2020, and (-5.15%) from 2019 to 2021 (Furst et al., 2022). There were also significant increases in the number of OTPs per one million persons per state over the past decade, but no significant increases from 2019 compared to 2021. These findings point to the necessity for more OTPs to combat the escalating OUD problem. Twenty states showed a reduction in OTPs from 2010 to 2021 which could be due to funding issues or policies for OTPs in these states (Smith, 2010).

Looking at how the COVID-19 pandemic affected OUD treatment from 2019 to 2021, the findings of this study show methadone distribution to OTPs did not increase significantly over this period. Poison control reports involving intentional methadone exposure showed a subtle (+5.0%) but significant, increase during this period (Welsh et al., 2022). In addition, the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) reported that drug overdose mortality increased by +31% between 2019 and 2020. However, the rate of methadone overdose deaths remained low with no significant increase in this report, suggesting no change in methadone misuse during the COVID-19 pandemic (Hedegaard et al., 2021). Since OTPs were not distributing additional methadone during the ongoing COVID-19 pandemic, this emphasizes the need for methadone treatment, as well as the necessity for safe storage and expanded availability to prevent opioid overdoses. It may be worth exploring options such as allowing for limited take home access at community pharmacies after a period of OUD stability, which is currently prohibited by law outside

of an OTP. Another uncommonly employed solution is to provide travelling methadone treatment on a daily route which can allow observed administration and decrease need for transportation to a further location (Breve et al., 2022).

As of 2018, forty-one states had methadone covered under Medicaid (Kaiser Family Foundation, 2019). Despite methadone being an evidence-based treatment of OUD and pain management, twelve states located predominantly in the South and Midwest opted to not expand Medicaid, leaving patients in these areas vulnerable to inaccessible treatment for OUD and for pain (Grissinger, 2011; Kaiser Family Foundation, 2021). States where methadone was not covered included: Arkansas, Idaho, Kansas, Kentucky, Louisiana, Nebraska, North Dakota, South Carolina, Tennessee, and Wyoming (Kaiser Family Foundation, 2019). Although over four fifths of states can, in theory, treat Medicaid patients with methadone for OUD, we found that only seven states accounted for the preponderance (98.47%) of prescriptions. This pronounced disparity in methadone coverage under Medicaid between states indicates that patients in certain states and regions have better access to this evidence-based treatment for OUD than others (Anderson & Kearney, 2000). Moving forward, improvements in access to methadone prescriptions and clinics for Medicaid patients need to be expanded in order to equalize treatment options for this large, but vulnerable, population. Having coverage for methadone under Medicaid in all fifty states will help combat the escalating opioid epidemic by expanding treatment of SUD and OUD (Kaiser Family Foundation, 2019). There is also a need for grant funding request for proposals to specifically focus on programs aimed at increasing access to methadone, particularly in rural areas.

This study suggests the importance of policy change as it is apparent there is a pressing need for additional access to OUD therapy, specifically methadone treatment, in the US. Over 400,000 people in the US received methadone from an OTP pre-pandemic, 2019, with over 90% located in urban areas, making it challenging for rural patients to make the daily trip to receive their medication (The Pew Charitable Trusts, 2021; Hyde et al., 2021). SAMHSA released guidelines in March 2020 allowing the regulatory authorities of all states to request blanket exceptions to allow OTP patients to take home doses of methadone and buprenorphine (Substance Abuse Mental Health Services Administration, 2022). These guidelines were extended in November 2021, and many providers and public health researchers are calling for these take home dosage rules to be continued post-pandemic (Amram et al., 2021; Regulatory Studies Center, 2021). The number of pharmacies which dispensed buprenorphine was 34-fold greater in 2021 than the number of OTPs that dispensed methadone. It is currently curious that there are more restrictions in the US for prescribing methadone than for other Schedule II substances like fentanyl or oxycodone. Overcoming the "Not in my Backyard" (NIMBY) stigma surrounding OTPs is not a trivial undertaking (Smith, 2010). It will require a paradigm shift to allow supervised administration in pharmacies, primary care offices, and mobile units as in other Western nations (Calcaterra et al., 2019; Joudrey et al., 2021; Gibbons et al., 2022). Expanding the role of specialty trained Board Certified Psychiatric Pharmacists by loosening the medication for opioid use disorder (MOUD) regulations to allow already prescribing pharmacists to obtain an X-DEA number, can immediately increase access to MOUD (Peckham et al., 2021).

The strengths of this report include novel and timely data from ARCOS which is

comprehensive for both distribution and number of distributors. Potential caveats and limitations stem from the fact that methadone distribution is reported in ARCOS by weight rather than prescriptions. Importantly, other pharmacoepidemiological research that compared another Schedule II substance from ARCOS to a state Prescription Drug Monitoring Program identified a high correspondence (r = +.985) (Piper et al., 2021). The inclusion of Medicaid data also, at least partially, offsets this concern. The paucity of methadone OTPs across rural states like Wyoming (253k km^2), South Dakota (200k km^2), and Nebraska (200 km^2) is an important finding. However, prior research found that another rural state, Maine, which ranked tenth in the US, had three-OTPs in a single thirty-thousand-person city (Bangor) and none in other areas in northern Maine (Hyde et al., 2021). The non-homogenous distribution within states should also be a concern for policy makers. Providing funding opportunities to train Addiction Medicine Fellows who will focus on rural care post-graduation can result in a pipeline of addiction medicine leaders to many areas of the US which are most in need. Future research should also be focused on determining which patient subgroups were most impacted by the reversal in methadone distribution. As the number of pharmacies nationally distributing buprenorphine decreased (-4.7%) from 2019 to 2021, further research should evaluate if both methadone and buprenorphine continue (Supplemental Table 1) to be underutilized in the post-COVID-19 pandemic period.

Conclusions

In conclusion, this study identified a reversal over the past-decade in the distribution of methadone for OUD in the US. The pronounced OTP geographical disparities, particularly in rural and western states, is a long-standing concern. The

many policy accommodations to COVID-19 may present an important opportunity to

determine which factors most impact the accessibility, adherence, and efficacy of

methadone.

Figure 1. Percent change from 2010 to 2020 in methadone distribution as reported by the Drug Enforcement Administration's Automated Reports and Consolidated Ordering System for Opioid Use Disorder. Percent change between 1.5 SDs and 1.959 SDs from the mean (+96.96%, SD = 146.64%), indicated with a #. Percent change > ±1.96 SD from the mean was considered significant (*P < 0.05).

Figure 2. Percent change from 2015 to 2020 in methadone distribution as reported by the Drug Enforcement Administration's Automated Reports and Consolidated Ordering System for Opioid Use Disorder. Percent change between 1.5 SDs and 1.959 SDs from the mean (+26.22%, SD = 50.38%), indicated with a #. Percent change > ±1.96 SD from the mean was considered significant (*P < 0.05).

Figure 3. Percent change from 2019 to 2020 in methadone distribution as reported by the Drug Enforcement Administration's Automated Reports and Consolidated Ordering System for Opioid Use Disorder. Percent change between 1.5 SDs and 1.959 SDs from the mean (-0.09%, SD 10.81), indicated with a #. Percent change ±1.96 SD from the mean considered significant (*P < 0.05).

Figure 4. Percent change from 2019 to 2021 in methadone distribution as reported by the Drug Enforcement Administration's Automated Reports and Consolidated Ordering System for Opioid Use Disorder. Percent change between 1.5 SDs and 1.959 SDs from the mean (-5.15%, SD 19.14), indicated with a #. Percent change ±1.96 SD from the mean considered significant (*P < 0.05).

Figure 5. Number of opioid treatment programs per 1 million persons per state all

significantly (P < 0.0001) different from 2010, 2015, 2020 and 2021. The twenty states

that decreased in 2021 relative to 2010, 2015 or 2020 are indicated with a "d". DC:

District of Columbia.

Figure 6. Seven states prescribed 98.47% of all methadone prescriptions to Medicaid

patients in the US in 2020 (top). Methadone prescriptions, per 100K Medicaid patients,

for the other 44 US states, and Washington DC (bottom).

Supplemental Figure 1. Distribution in kg (A) and number of buyers and registrants (B)

in Opioid Treatment Programs (OTP) and pharmacies (pharm, buprenorphine only) for

methadone and buprenorphine as reported to the United States Drug Enforcement

Administration's Automated Reports and Consolidated Orders system for the fifty states,

Washington DC, and the US Territories. Methadone in 2021 (12.4 metric tons) was

5.69% lower than 2019 (13.1 metric tons) and 5.71% below 2020 (13.1 metric tons).

Methadone by weight was 2.49-fold greater than buprenorphine from pharmacies and

OTPs in 2021. The number of pharmacies distributing buprenorphine was 33.3 to 47.3-

fold greater than the number of OTPs distributing methadone from 2010 to 2021.

Supplemental Table 1. Comparison of the pharmacological and therapeutic properties of methadone and buprenorphine. [b]buccal formulation, [C]complimentary

	methadone	buprenorphine
Year developed	1937	1969
Opioid receptor activity	mu full-agonist	mu partial agonist
Other mechanism(s)	NMDA antagonist	non-selective for other opioid receptors
Potency (x morphine)	8 – 12	10
Metabolism	CYP2D6, CYP3A4	CYP3A4
Active metabolite(s)	none	norbuprenorphine
Half-life	8 – 59 hours for oral	24 – 48 hours for buccal
Formulation	mono	mono or combination with naloxone
Present in breast milk	yes, < 3% maternal dose	yes, < 1% maternal dose
Availability (US)	narcotic treatment programs	providers with an X-waiver
Schedule (US)	II	III
Crowdsource (price/mg)	$0.96	$2.13
Black box warnings	addiction, abuse, misuse, QT prolongation	addiction, abuse, misuse[b], child exposure can result in overdose
Opioid rank	#1	#4
WHO Essential Medication[C]	yes	yes

Supplemental Table 2. Medicaid's State Drug Utilization Data reported National Drug

Codes (NDC) for methadone prescribed for opioid use disorder.

NDC
54039168
54039268
54355344
54355563
54421825
54421925
54453825
54457025
54457125
54855324
54855424
406052710
406054034
406254001
406575501
406575523
406575562
406577101
406577123
406577162
406872510
904653061
13107000000
17478000000
31722000000
42806000000
60687000000
63739000000
66689000000
67457000000
67877000000
68084000000
68462000000

Supplemental Table 3. Opioid treatment programs as reported to the Drug Enforcement Administration's Automated Reports and Consolidated Orders System per one million persons.

State	2010	2015	2020	2021
1. Rhode Island	16.1	16.1	21.0	24.6
2. Delaware	6.7	10.6	14.1	17.9
3. Maryland	9.9	11.4	14.4	14.3
4. Connecticut	10.1	10.3	11.9	14.1
5. Massachusetts	7.9	9.1	12.1	13.7
6. Vermont	11.2	14.4	12.4	12.4
7. New Mexico	4.8	6.7	11.3	9.5
8. Arizona	5.0	5.7	9.2	9.3
9. DC	8.3	5.9	7.3	9.0
10. Alaska	2.8	5.4	5.5	8.2
11. Maine	6.8	9.0	7.3	7.3
12. Illinois	5.1	5.6	7.2	7.2
13. Pennsylvania	5.4	5.8	6.9	7.0
14. Georgia	4.7	6.3	7.0	6.7
15. Kentucky	3.0	3.4	6.2	6.4
16. North Carolina	3.8	5.1	7.9	6.4
17. Iowa	1.3	2.2	5.6	6.0
18. New York	5.7	5.3	6.0	5.8
19. New Hampshire	4.6	6.0	7.3	5.8
20. Ohio	1.5	1.8	4.8	5.5
21. Oregon	3.4	3.7	5.2	5.4
22. Nevada	4.4	4.5	5.2	5.4
23. Utah	3.6	4.4	5.5	5.1
24. West Virginia	4.9	4.9	5.0	5.0
25. Oklahoma	3.7	3.6	5.3	5.0
26. Colorado	2.2	2.6	4.9	5.0
27. Michigan	3.3	4.3	4.5	4.8
28. New Jersey	0.11	3.7	4.7	4.7
29. Virginia	2.1	3.6	4.5	4.7
30. South Carolina	1.9	3.7	4.7	4.6
31. California	3.8	3.8	4.0	4.2
32. North Dakota	0.0	0.0	3.8	3.9
33. Wisconsin	2.3	3.0	3.7	3.7
34. Montana	2.0	2.9	3.7	3.6
35. Indiana	2.2	2.1	3.4	3.5
36. Washington	3.0	3.0	3.9	3.5
37. Alabama	2.9	4.5	4.6	3.2
38. Texas	3.3	3.2	3.3	3.1
39. Kansas	2.5	3.1	3.1	3.1
40. Minnesota	1.5	3.3	2.8	3.0

41. Missouri	1.7	2.5	2.6	2.9
42. Tennessee	1.9	1.8	2.3	2.9
43. Louisiana	1.8	2.1	2.2	2.8
44. Hawaii	2.9	2.8	2.8	2.8
45. Florida	1.3	2.6	2.9	2.5
46. Idaho	1.9	1.8	2.2	2.1
47. Arkansas	1.0	2.0	2.0	2.0
48. South Dakota	0.0	1.2	1.1	1.1
49. Nebraska	1.6	1.6	1.5	1.0
50. Mississippi	0.3	0.3	1.7	1.0
51. Wyoming	0.0	0.0	0.0	0.0
Mean	**3.8**	**4.6**	**5.7**	**5.9**
SEM	**0.4**	**0.5**	**0.6**	**0.6**

Acknowledgments

Thank you to Iris Johnston for providing access to journal articles, and Olapeju

Simoyan, MD for providing feedback.

References

Amram, O., Amiri, S., Panwala, V., Lutz, R., Joudrey, P. J., & Socias, E. (2021). The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. *American Journal of Drug and Alcohol Abuse*, *47*(6), 722–729. https://doi.org/10.1080/00952990.2021.1979991

Anderson, I. B., & Kearney, T. E. (2000). Use of methadone. *The Western Journal of Medicine*, *172*(1), 43–46. https://doi.org/10.1136/ewjm.172.1.43

Bandara, S., Kennedy-Hendricks, A., Merritt, S., Barry, C. L., & Saloner, B. (2020). Early effects of COVID-19 on programs providing medications for Opioid Use Disorder in jails and prisons. *Journal of Addiction Medicine*, *14*(5), e257–e260. https://doi.org/10.1097/ADM.0000000000000718

Bandara, S., Kennedy-Hendricks, A., Merritt, S., Barry, C. L., & Saloner, B. (2021). Methadone and buprenorphine treatment in United States jails and prisons: Lessons from early adopters. *Addiction*, *116*(12), 3473–3481. https://doi.org/10.1111/add.15565

Breve, F., Batastini, L., LeQuang, J. A. K., Marcharndo, G. (2022). Mobile narcotic treatment programs: On the road again? *Cureus, 14*(3), e23221. https://doi.org/10.7759/cureus.23221

Cabrera, F. F., Gamarra, E. R., Garcia, T. E., Littlejohn, A. D., Chinga, P. A., Pinentel-Morillo, L. D., Tirado, J. R., Chung, D. Y., Pande, L. J., McCall, K. L., Nichols, S. D., & Piper, B. J. (2019). Opioid distribution trends (2006–2017) in the US Territories. *PeerJ*, *2019*(1), 1–12. https://doi.org/10.7717/peerj.6272

Calcaterra, S. L., Bach, P., Chadi, A., Chadi, N., Kimmel, S. D., Morford, K. L., Roy, P., & Samet, J. H. (2019). Methadone matters: What the United States can learn from the global effort to treat opioid addiction. *Journal of General Internal Medicine*, *34*(6), 1039–1042. https://doi.org/10.1007/s11606-018-4801-3

Centers for Disease Control and Prevention. (2021). *Drug Overdose Deaths in the U.S. Top 100,000 Annually*. Retrieved from https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm. Accessed March 31, 2022

Centers for Disease Control and Prevention. (2022). *Vital Statistics - Rapid Release Provisional Drug Overdose Death Counts*. Retrieved from https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed February 22, 2022

Chorniy, A., Currie, J., & Sonchak, L. (2018). Exploding asthma and ADHD caseloads: The role of Medicaid managed care. *Journal of Health Economics*, *60*, 1–15. https://doi.org/10.1016/j.jhealeco.2018.04.002

Chow, R. M., & Issa, M. (2017). Use of methadone. *Pain Medicine: An Essential Review*, *172*(January), 157–158. https://doi.org/10.1007/978-3-319-43133-8_38

Darracq, M. A., & Thornton, S. L. (2021). Respiratory depression following medications for opioid use disorder (MOUD)-approved buprenorphine product oral exposures; National Poison Database System 2003-2019. *Clinical Toxicology (Philadelphia, Pa.)*, *59*(4), 303–312. https://doi.org/10.1080/15563650.2020.1814318

Friedman, J., & Akre, S. (2021). COVID-19 and the drug overdose crisis: Uncovering the deadliest months in the United States, January–July 2020. *American Journal of Public Health*, *111*(7), 1284–1291. https://doi.org/10.2105/AJPH.2021.306256

Friedman, J.R., Hansen, H. (2022). Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic. *JAMA Psychiatry*, *79*(4), 379–381. https://doi.org/10.1001/jamapsychiatry.2022.0004

Furst, J. A., Mynarski, N. J., McCall, K. L., & Piper, B. J. (2022). Pronounced regional disparities in United States methadone distribution. Annals of Pharmacotherapy, 56(3), 271–279. https://doi.org/10.1177/10600280211028262

Gibbons, J. B., Stuart, E. A., & Saloner, B. (2022). Methadone on wheels-A new option to expand access to care through mobile units. *JAMA Psychiatry*, *79*(3), 187–188. https://doi.org/10.1001/jamapsychiatry.2021.3716

Grissinger M. (2011). Keeping patients safe from methadone overdoses. *P & T: 36*(8), 462–466.

Hedegaard, H., Miniño, A. M., Spencer, M. R., & Warner, M. (2021). Drug overdose deaths in the United States, 1999-2020. *NCHS Data Brief*, *426*, 1–8.

Hyde, T. F., Bekoe-Tabiri, A. D., Kropp Lopez, A. K., Devia, L. G., Gutierrez, B. D., Lara, M. C., Soto, A. R., Kaufman, D. E., Moran, M. T., Simpson, K. J., Shah, D. T., Foster, M., Desrosiers, C. E., Hebert, J., Nichols, S. D., McCall, K. L., & Piper, B. J. (2021). County and demographic differences in drug arrests and controlled substance use in Maine. *Journal of Maine Medical Center, 3*(2), Article 2. https://doi.org/10.46804/2641-2225.1074

Jones, C. M., Byrd, D. J., Clarke, T. J., Campbell, T. B., Ohuoha, C., & McCance-Katz, E. F. (2019). Characteristics and current clinical practices of opioid treatment programs in the United States. *Drug and Alcohol Dependence*, *205*(August 2019), 107616. https://doi.org/10.1016/j.drugalcdep.2019.107616

Jones, C. M., Compton, W. M., Han, B., Baldwin, G., & Volkow, N. D. (2022). Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs. *JAMA Psychiatry, 79*(9), 932–934. https://doi.org/10.1001/jamapsychiatry.2022.1776

Joudrey, P. J., Adams, Z. M., Bach, P., Van Buren, S., Chaiton, J. A., Ehrenfeld, L., Guerra, M. E., Gleeson, B., Kimmel, S. D., Medley, A., Mekideche, W., Paquet, M., Sung, M., Wang, M., You Kheang, R. O. O., Zhang, J., Wang, E. A., & Edelman, E. J. (2021). Methadone access for Opioid Use Disorder during the COVID-19 pandemic within the United States and Canada. *JAMA Network Open*, *4*(7), 1–13. https://doi.org/10.1001/jamanetworkopen.2021.18223

Kaiser Family Foundation. (2019). *Medicaid's role in addressing the opioid epidemic*. Retrieved from https://www.kff.org/infographic/medicaids-role-in-addressing-opioid-epidemic/. Accessed September 22, 2022

Kaiser Family Foundation. (2021). *Status of State Action on the Medicaid Expansion Decision*. Retrieved from https://www.kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Accessed September 22, 2022

Kaufman, D. E., Kennalley, A. L., M., McCall, K. L., & Piper, B. J. (2022). Methadone overdoses increased 48% during the COVID-19 epidemic. *MedRxiv*. https://doi.org/10.1101/2022.04.14.22273870

Kennalley, A. L., Boureghda, Y. A., Ganesh, J. G., Watkins, A. M., McCall, K. L., & Piper, B. J. (2022). Declining national codeine distribution in United States hospitals and pharmacies from 2011 to 2019. *MedRxiv*. https://doi.org/10.1101/2022.04.12.22273805

Kennalley, A. L., Furst, J. A., Mynarski, N. J., McCall, K. L., & Piper, B. J. (2021). Methadone distribution increased from 2010 to 2019 for Opioid Use Disorder treatment in the US. *MedRxiv*. https://doi.org/10.1101/2022.03.09.22272154

Lagisetty, P. A., Ross, R., Bohnert, A., Clay, M., & Maust, D. T. (2019). Buprenorphine treatment divide by race/ethnicity and payment. *JAMA Psychiatry*, *76*(9), 979–981. https://doi.org/10.1001/jamapsychiatry.2019.0876

Maine Department of Corrections. (2020). *Medication Assisted Treatment Services First Year Review*. Retrieved from https://www.maine.gov/corrections/sites/maine.gov.corrections/files/inline-files/MAT_Year_One_ReviewFinal.pdf. Accessed October 19, 2022.

Marsch, L. A. (1998). The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. *Addiction*, *93*(4), 515–532. https://doi.org/10.1046/j.1360-0443.1998.9345157.x

Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, *2014*(2). https://doi.org/10.1002/14651858.CD002207.pub4

Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews, 2009*(3), CD002209. https://doi.org/10.1002/14651858.CD002209.pub2

Medicaid.gov. (2021). *State Drug Utilization Data* [Data set]. https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html

Otiashvili, D., Piralishvili, G., Sikharulidze, Z., Kamkamidze, G., Poole, S., & Woody, G. E. (2013). Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-outcomes of a randomized trial. *Drug and Alcohol Dependence*, *133*(2), 376–382. https://doi.org/10.1016/j.drugalcdep.2013.06.024

Peckham, A. M., Ball, J., Colvard, M. D., Dadiomov, D., Hill, L. G., Nichols, S. D., Tallian, K., Ventricelli, D. J., & Tran, T. H. (2021). Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. *American Journal of Health-System Pharmacy, 78*(7), 613–618. https://doi.org/10.1093/ajhp/zxab003

Peterkin, A., Laks, J., & Weinstein, Z. M. (2022). Current best practices for acute and chronic management of patients with Opioid Use Disorder. *Medical Clinics of North America*, *106*(1), 61–80. https://doi.org/10.1016/j.mcna.2021.08.009

Piper, B. J., Shah, D. T., Simoyan, O. M., Mccall, K. L., & Nichols, S. D. (2021). Trends in medical use of opioids in the U.S., 2006–2016. *American Journal of Preventive Medicine*, *54*(5), 652–660. https://doi.org/10.1016/j.amepre.2018.01.034

Regulatory Studies Center. (2021). *Extending Pandemic Flexibilities for Opioid Use Disorder Treatment*. Retrieved from https://regulatorystudies.columbian.gwu.edu/extending-pandemic-flexibilities-opioid-use-disorder-treatment. Accessed March 2, 2022

Smith C. B. (2010). Socio-spatial stigmatization and the contested space of addiction treatment: remapping strategies of opposition to the disorder of drugs. *Social*

Science & Medicine (1982), *70*(6), 859–866.
https://doi.org/10.1016/j.socscimed.2009.10.033

Substance Abuse Mental Health Services Administration. (2022). *Methadone take-home flexibilities extension guidance*. Retrieved from https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines/methadone-guidance. Accessed February 15, 2022

Substance Abuse and Mental Health Services Administration. (2020). *Opioid Treatment Program (OTP) Guidance. 7*, 20857. https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf

The Pew Charitable Trusts. (2021). *More flexible methadone access should continue post-pandemic.* Retrieved from https://www.pewtrusts.org/en/research-and-analysis/articles/2021/04/22/more-flexible-methadone-access-should-continue-post-pandemic. Accessed March 31, 2022

Toce, M. S., Chai, P. R., Burns, M. M., & Boyer, E. W. (2018). Pharmacologic treatment of Opioid Use Disorder: A review of pharmacotherapy, adjuncts, and toxicity. *Journal of Medical Toxicology*, *14*(4), 306–322. https://doi.org/10.1007/s13181-018-0685-1

United States Census Bureau. (2021). *Resident Population for the 50 States, the District of Columbia, and Puerto Rico: 2020 Census* [Data set]. https://www.census.gov/topics/population.html

U.S. Food & Drug Administration. (2022). *Buprenorphine: Drug Safety Communication - FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain*. Retrieved from https://www.fda.gov/safety/medical-product-safety-information/buprenorphine-drug-safety-communication-fda-warns-about-dental-problems-buprenorphine-medicines. Accessed March 2, 2022

Welsh, C., Doyon, S., & Hart, K. (2022). Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations*. International Journal on Drug Policy*, 102, 103591. https://doi.org/10.1016/j.drugpo.2022.103591